Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 9550

Next Previous
Drug Profile

AZD 9550

Alternative Names: AZD-9550

Latest Information Update: 06 Nov 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Hepatoprotectants; Obesity therapies; Peptides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity

Most Recent Events

  • 02 Nov 2026 AstraZeneca plans a phase I trial for Obesity (In volunteers) in United Kingdom (SC, Injection) (NCT07911514)
  • 20 Mar 2026 AstraZeneca initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in USA (SC)(NCT07546760)
  • 18 Feb 2025 AstraZeneca completes the phase-II ASCEND trials in Obesity (Monotherapy, Combination therapy) in Australia, Canada, Germany, Japan, and the US (NCT06862791)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top